Endobronchial Ultrasound Biopsy Market Size
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR (2024 - 2029) | 4.36 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Endobronchial Ultrasound Biopsy Market Analysis
The Endobronchial Ultrasound Biopsy Market is expected to register a CAGR of 4.36% during the forecast period.
Respiratory disorders such as chronic obstructive pulmonary disorder (COPD), tuberculosis, and lung and bronchus cancer use endobronchial ultrasound biopsy to obtain tissue or fluid samples from the lungs and surrounding lymph nodes without conventional surgery to diagnose and detect the severity of diseases. For instance, according to 2024 statistics published by the American Lung Association, an estimated 11.7 million, or 4.6% of the adult population, in the United States were given a COPD diagnosis in 2022. This translates to a large patient pool potentially requiring diagnosis. Similarly, according to the Australian Bureau of Statistics 2022 update, adults aged 65 years and above are significantly more likely to have COPD, with roughly one in fourteen (7.0%) being diagnosed. Therefore, the rising prevalence of respiratory disorders is a potential driver for the endobronchial ultrasound biopsy market.
Additionally, while smoking is the leading cause of COPD, particularly in high-income countries, household air pollution is another significant risk factor in low- and middle-income countries (LMICs). This is especially concerning as smoking rates are on the rise in LMICs, suggesting a potential explosion of COPD cases in the coming decades. As the global COPD burden grows, particularly in LMICs, the demand for accurate and early diagnosis tools like EBUS is expected to rise in the near future. This overall growth in respiratory illnesses is likely to drive up the demand for accurate and minimally invasive diagnostic tools like EBUS during the forecast period.
Furthermore, according to the World Health Organization Report 2023, an estimated global total of 10.6 million people (ranging from 9.9 to 11.4 million) contracted TB, translating to 133 incident cases per 100,000 individuals. The majority of TB cases in 2022 were concentrated in the WHO regions of Southeast Asia (46%), Africa (23%), and the Western Pacific (18%), with smaller proportions in the Eastern Mediterranean (8.1%), the Americas (3.1%), and Europe (2.2%) in 2022. While TB primarily affects the lungs, it can also spread to other parts of the body (extrapulmonary TB). EBUS can be a valuable tool in diagnosing extrapulmonary TB cases by guiding needle biopsies of lymph nodes or other affected tissues. The number of tuberculosis (TB) cases is expected to rise, further fueling the demand for endobronchial ultrasound biopsy for this specific region.
Therefore, owing to the aforementioned factors, such as the high burden of respiratory diseases and increasing demand for minimally invasive procedures, the market is anticipated to witness growth during the forecast period. However, the high cost of equipment and lack of reimbursement policies in developing countries are likely to restrain the market's growth.
Endobronchial Ultrasound Biopsy Market Trends
The Cancer Diagnosis Segment is Expected to Hold a Significant Share in the Market During the Forecast Period
The main indications of endobronchial ultrasound (EBUS) include primary diagnosis, staging, and restaging of lung cancer. The cancer segment is expected to register a significant growth rate during the forecast period owing to the rising burden of lung cancer worldwide, the rising adoption of endobronchial ultrasound biopsy for cancer diagnosis and increasing technological advancements.
The increasing prevalence of lung cancer is a significant driver for EBUS use in diagnosis and staging. The rising burden of lung cancer cases is expected to propel the market's growth. For instance, according to the American Cancer Society (ACS) Cancer Statistics 2024, 2 million new cancer cases are expected to be diagnosed in the United States in 2024, compared to 1.9 million in 2023. Out of the total cancer cases, 234.5 thousand new cases are estimated to be lung and bronchus cancer in 2024. EBUS offers a minimally invasive way to obtain tissue samples compared to traditional surgical biopsies. Therefore, the rising lung cancer cases in the region are expected to propel the demand for endobronchial ultrasound biopsy as it is a minimally invasive procedure that can be performed using local anesthesia and moderate sedation.
Furthermore, newer EBUS bronchoscopes boast improved image quality, allowing for more precise visualization of lung structures and abnormalities. This leads to better targeting of biopsy sites and a higher diagnostic yield. For instance, according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), in 2024, EUBS allows for earlier detection of lung cancer by reaching peripheral lung lesions that might be missed by other methods. It also helps in staging cancer, which is crucial for treatment planning. Therefore, it is reported that EBUS biopsy is an important method of diagnosis, and staging of the lung is useful in lung cancer.
Additionally, the rising launches of innovative endobronchial ultrasound biopsy devices by market players are contributing significantly to the market growth. For instance, in October 2023, Praxis Medical, a medical device company, received approval from the FDA for its EndoCore endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) fine needle biopsy device. This is a significant advancement in the diagnosis of lung cancer and other lung diseases, and it is expected to develop and market innovative devices during the forecast period.
Therefore, owing to the aforementioned factors, such as the rising burden of cancer, increasing adoption of endobronchial ultrasound biopsy, and new product launches by market players, the segment is expected to register a significant growth rate during the forecast period.
North America is Expected to Cover a Large Share of the Market During the Forecast Period
North America is expected to hold a significant market share in the endobronchial ultrasound biopsy market owing to factors such as the high burden of lung cancer and other respiratory diseases, such as COPD and TB, rising research and development spending on disease diagnostics, and the high concentration of market players in the region.
The increasing number of respiratory diseases in Canada drives the demand for minimally invasive EBUS technology. According to the Canadian Cancer Society's May 2022, it was estimated that 30 thousand Canadians would be diagnosed with lung and bronchus cancer, representing 13% of new cancer cases in 2022. Also, a research study published in Biosystems Journal in January 2022 used Electronic Medical Record (EMR) data from primary care clinics in seven provinces across Canada to develop predictive models to identify COPD in the Canadian population. The study stated that approximately 10% of Canadians aged 35 years or older were living with COPD. Therefore, the high burden of such diseases is expected to propel the demand for EBUS biopsy for the early and effective diagnosis of such diseases, which is expected to propel the market's growth in the region.
Furthermore, according to the Condition and Disease Categories (RCDC), in the May 2024 update, the spending on R&D in the United States for COPD was USD 148 million in 2023, USD 595 million in 2023 for tuberculosis, and USD 504 million for lung cancer in 2023. Therefore, the high spending on respiratory diseases research is expected to boost the development of innovative EBUS biopsy devices in the nation, which is further expected to augment the market's growth during the forecast period.
Therefore, the aforementioned factors, such as the high burden of respiratory diseases and government grants for R&D of various respiratory diseases, are expected to create opportunities for market players to accelerate the development of innovative biopsy devices in North America.
Endobronchial Ultrasound Biopsy Industry Overview
The endobronchial ultrasound biopsy market is fragmented in nature due to the presence of several global and local market players. Some key market players are Medtronic, Boston Scientific Corporation, CONMED Corporation, Olympus Corporation, Cook Group, ENDO-FLEX GmbH, CLINODEVICE, Medi-Globe GmbH, and Micro-Tech Endoscopy. Competition will likely intensify as established players refine their technologies and new entrants bring innovative solutions. Advancements in AI, fusion imaging, and cost-effective solutions are expected to drive the market's growth.
Endobronchial Ultrasound Biopsy Market Leaders
-
Boston Scientific Corporation
-
CONMED Corporation
-
Olympus Corporation
-
Medtronic
-
Cook Group
*Disclaimer: Major Players sorted in no particular order
Endobronchial Ultrasound Biopsy Market News
- September 2023: Roncus Medical launched the BioStar Transbronchial Aspiration Needle (TBNA). This innovative needle is designed for minimally invasive lung tissue acquisition during EBUS procedures, aiding in the diagnosis and staging of lung cancer.
- February 2023: TransMed launched Concorde US ultrasound-guided soft-tissue biopsy devices that have been used in a series of clinical cases.
Endobronchial Ultrasound Biopsy Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Geriatric Population
- 4.2.2 Increasing Prevalence of Respiratory Disorders
- 4.2.3 Increasing demand for Minimally Invasive Procedures
-
4.3 Market Restraints
- 4.3.1 High Cost of Equipment
- 4.3.2 Lack Reimbursement Policies in Developing Countries
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Product
- 5.1.1 Biopsy Forceps
- 5.1.2 Cytology Brushes
- 5.1.3 Biopsy Needles
- 5.1.4 Transbronchial Aspiration Needles
- 5.1.5 Spray Catheters
- 5.1.6 Other Products
-
5.2 By Application
- 5.2.1 Cancer Diagnosis
- 5.2.2 Infection Diagnosis
- 5.2.3 Other Applications
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 ACE Medical Devices Pvt. Ltd
- 6.1.2 Boston Scientific Corporation
- 6.1.3 CLINODEVICE
- 6.1.4 CONMED Corporation
- 6.1.5 Cook Group
- 6.1.6 ENDO-FLEX GmbH
- 6.1.7 Medi-Globe GmbH
- 6.1.8 Medtronic
- 6.1.9 Micro-Tech Endoscopy
- 6.1.10 Olympus Corporation
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Endobronchial Ultrasound Biopsy Industry Segmentation
As per the scope of the report, endobronchial ultrasound is a technique for biopsy and visualization of the structure around the tracheobronchial tree.
The endobronchial ultrasound biopsy market is segmented by product, application, and geography. By product, the market is segmented into biopsy forceps, cytology brushes, biopsy needles, transbronchial aspiration needles, spray catheters, and other products. By application, the market is segmented into cancer diagnosis, infection diagnosis, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (USD) for the above segments.
| By Product | Biopsy Forceps | |
| Cytology Brushes | ||
| Biopsy Needles | ||
| Transbronchial Aspiration Needles | ||
| Spray Catheters | ||
| Other Products | ||
| By Application | Cancer Diagnosis | |
| Infection Diagnosis | ||
| Other Applications | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Endobronchial Ultrasound Biopsy Market Research FAQs
What is the current Endobronchial Ultrasound Biopsy Market size?
The Endobronchial Ultrasound Biopsy Market is projected to register a CAGR of 4.36% during the forecast period (2024-2029)
Who are the key players in Endobronchial Ultrasound Biopsy Market?
Boston Scientific Corporation, CONMED Corporation, Olympus Corporation, Medtronic and Cook Group are the major companies operating in the Endobronchial Ultrasound Biopsy Market.
Which is the fastest growing region in Endobronchial Ultrasound Biopsy Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Endobronchial Ultrasound Biopsy Market?
In 2024, the North America accounts for the largest market share in Endobronchial Ultrasound Biopsy Market.
What years does this Endobronchial Ultrasound Biopsy Market cover?
The report covers the Endobronchial Ultrasound Biopsy Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Endobronchial Ultrasound Biopsy Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Endobronchial Ultrasound Biopsy Industry Report
Statistics for the 2024 Endobronchial Ultrasound Biopsy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Endobronchial Ultrasound Biopsy analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
